Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Rastogi, 2020
 
NCT04459247
RCTVitamin DplaceboCOVID-19 mild to moderateNA
16/24 suggested
  • suggested 5.3-fold increase in PCR-negative conversion (PE)
Espitia-Hernandez, 2020 NRaVitamin Dstandard of careCOVID 19 outpatients, COVID-19 mild to moderateNA
28/7 suggested
  • suggested 714.0-fold increase in PCR-negative conversion

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).